Glucocorticoid usage in giant cell arteritis over six decades (1950 to 2009)

A. Chandran, Pr D. Udayakumar, T. A. Kermani, Kenneth J Warrington, Cynthia Crowson, Eric Lawrence Matteson

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

OBJECTIVES: To evaluate the trends in glucocorticoid (GC) therapy in patients with giant cell arteritis (GCA).

METHODS: Using a population-based inception cohort, GC therapy details were collected for all patients with GCA diagnosed between 1950-2009. GC usage for patients diagnosed with GCA between 1980-2009 was compared to those diagnosed between 1950-1979.

RESULTS: The mean starting dose was similar in both time-periods but the mean cumulative dosages at different time points were significantly higher for patients diagnosed between 1980-2009 than in 1950-1979 (at 1-year: 6.3 vs. 4.1g; and at 5 years 10.7 vs. 7.6g, respectively, p<0.001). The median time to permanent discontinuation of GC was 2.6 years for 1980-2009 vs. 1.5 years for 1950-1979 (p=0.004). The risk for GC-associated adverse events was similar in both time periods (p=0.52).

CONCLUSIONS: GCA patients diagnosed in the last three decades were treated with higher cumulative GC doses and were less likely to achieve GC discontinuation. However, their risks for GC-related complications were not significantly higher than their earlier counterparts.

Original languageEnglish (US)
JournalClinical and Experimental Rheumatology
Volume33
Issue number2
StatePublished - Mar 1 2015

Fingerprint

Giant Cell Arteritis
Glucocorticoids
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Cite this

Glucocorticoid usage in giant cell arteritis over six decades (1950 to 2009). / Chandran, A.; Udayakumar, Pr D.; Kermani, T. A.; Warrington, Kenneth J; Crowson, Cynthia; Matteson, Eric Lawrence.

In: Clinical and Experimental Rheumatology, Vol. 33, No. 2, 01.03.2015.

Research output: Contribution to journalArticle

@article{8ff15146e90f42679558d17a78264123,
title = "Glucocorticoid usage in giant cell arteritis over six decades (1950 to 2009)",
abstract = "OBJECTIVES: To evaluate the trends in glucocorticoid (GC) therapy in patients with giant cell arteritis (GCA).METHODS: Using a population-based inception cohort, GC therapy details were collected for all patients with GCA diagnosed between 1950-2009. GC usage for patients diagnosed with GCA between 1980-2009 was compared to those diagnosed between 1950-1979.RESULTS: The mean starting dose was similar in both time-periods but the mean cumulative dosages at different time points were significantly higher for patients diagnosed between 1980-2009 than in 1950-1979 (at 1-year: 6.3 vs. 4.1g; and at 5 years 10.7 vs. 7.6g, respectively, p<0.001). The median time to permanent discontinuation of GC was 2.6 years for 1980-2009 vs. 1.5 years for 1950-1979 (p=0.004). The risk for GC-associated adverse events was similar in both time periods (p=0.52).CONCLUSIONS: GCA patients diagnosed in the last three decades were treated with higher cumulative GC doses and were less likely to achieve GC discontinuation. However, their risks for GC-related complications were not significantly higher than their earlier counterparts.",
author = "A. Chandran and Udayakumar, {Pr D.} and Kermani, {T. A.} and Warrington, {Kenneth J} and Cynthia Crowson and Matteson, {Eric Lawrence}",
year = "2015",
month = "3",
day = "1",
language = "English (US)",
volume = "33",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "2",

}

TY - JOUR

T1 - Glucocorticoid usage in giant cell arteritis over six decades (1950 to 2009)

AU - Chandran, A.

AU - Udayakumar, Pr D.

AU - Kermani, T. A.

AU - Warrington, Kenneth J

AU - Crowson, Cynthia

AU - Matteson, Eric Lawrence

PY - 2015/3/1

Y1 - 2015/3/1

N2 - OBJECTIVES: To evaluate the trends in glucocorticoid (GC) therapy in patients with giant cell arteritis (GCA).METHODS: Using a population-based inception cohort, GC therapy details were collected for all patients with GCA diagnosed between 1950-2009. GC usage for patients diagnosed with GCA between 1980-2009 was compared to those diagnosed between 1950-1979.RESULTS: The mean starting dose was similar in both time-periods but the mean cumulative dosages at different time points were significantly higher for patients diagnosed between 1980-2009 than in 1950-1979 (at 1-year: 6.3 vs. 4.1g; and at 5 years 10.7 vs. 7.6g, respectively, p<0.001). The median time to permanent discontinuation of GC was 2.6 years for 1980-2009 vs. 1.5 years for 1950-1979 (p=0.004). The risk for GC-associated adverse events was similar in both time periods (p=0.52).CONCLUSIONS: GCA patients diagnosed in the last three decades were treated with higher cumulative GC doses and were less likely to achieve GC discontinuation. However, their risks for GC-related complications were not significantly higher than their earlier counterparts.

AB - OBJECTIVES: To evaluate the trends in glucocorticoid (GC) therapy in patients with giant cell arteritis (GCA).METHODS: Using a population-based inception cohort, GC therapy details were collected for all patients with GCA diagnosed between 1950-2009. GC usage for patients diagnosed with GCA between 1980-2009 was compared to those diagnosed between 1950-1979.RESULTS: The mean starting dose was similar in both time-periods but the mean cumulative dosages at different time points were significantly higher for patients diagnosed between 1980-2009 than in 1950-1979 (at 1-year: 6.3 vs. 4.1g; and at 5 years 10.7 vs. 7.6g, respectively, p<0.001). The median time to permanent discontinuation of GC was 2.6 years for 1980-2009 vs. 1.5 years for 1950-1979 (p=0.004). The risk for GC-associated adverse events was similar in both time periods (p=0.52).CONCLUSIONS: GCA patients diagnosed in the last three decades were treated with higher cumulative GC doses and were less likely to achieve GC discontinuation. However, their risks for GC-related complications were not significantly higher than their earlier counterparts.

UR - http://www.scopus.com/inward/record.url?scp=85003360463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003360463&partnerID=8YFLogxK

M3 - Article

C2 - 26016757

AN - SCOPUS:85003360463

VL - 33

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 2

ER -